Dinutuximab beta (Qarziba)

Mechanism of action

Anti-GD2 antibody

2017-05-08: Initial authorisation as Qarziba. Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation. In patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin 2 (IL 2).
2017-05-08: Initial authorisation as Qarziba. Qarziba is indicated for the treatment of patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. Qarziba should be combined with interleukin 2 (IL 2).